Evidence map›Paper›PMID 31312646›Full record

ReviewVisceral medicine2019

Implications of Immunotherapy in Hepatobiliary Tumors.

Aline Gottlieb, Jan Best, Ali Canbay

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Visceral medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Aline GottliebDepartment of Gastroenterology, Hepatology, and Infectious Diseases, University Hospital Magdeburg, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Jan BestDepartment of Gastroenterology, Hepatology, and Infectious Diseases, University Hospital Magdeburg, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Ali CanbayDepartment of Gastroenterology, Hepatology, and Infectious Diseases, University Hospital Magdeburg, Otto von Guericke University Magdeburg, Magdeburg, Germany.
University Hospital Magdeburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related death worldwide. Upon ineligibility for resection, liver transplantation, or locoregional therapies, sorafenib has been the only systemic treatment option of advanced HCC for more than a decade. Immunotherapy is an evolving HCC treatment option that has shown promise in treatment efficacy at an acceptable safety profile during several preceding phase I/II trials. Numerous clinical trials of immune checkpoint inhibitors (ICPIs) alone, in combination of two, or combined with other targeted or locoregional therapies are ongoing. Encouraging results of two-phase III trials testing pembrolizumab or nivolumab versus standard care therapy even resulted in Food and Drug Administration approval for second-line treatment of advanced HCC. ICPIs may open new avenues to the treatment of hepatobiliary tumors, alone or in combination.

Indexed as

Cytotoxic T-lymphocyte-associated protein 4 antibodyHepatocellular carcinomaImmune checkpoint inhibitorsImmunotherapyProgrammed cell death protein 1 antibodyProgrammed death ligand 1 antibodyTargeted therapy

Identifiers

PMID31312646
PMCPMC6597927
OpenAlexW2914124850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.